Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00HYK
|
|||
| Former ID |
DIB009549
|
|||
| Drug Name |
AFN-1252
|
|||
| Synonyms |
API-1252; API-1401; Antibacterial therapeutics, Affinium; Antibacterials, Affinium; Bacterial fatty acid biosynthesis inhibitors, Affinium; Galapagos program, Affinium; Antibacterial therapeutics, Affinium/GSK; Antibacterials, Affinium/GSK; FabI inhibitors (antibacterial), Affinium; AFN-1252 (oral, bacterial infection); AFN-1252 (oral, bacterial infection), Affinium
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Staphylococcus infection [ICD-11: 1B5Y] | Phase 2 | [1] | |
| Company |
Affinium pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H21N3O3
|
|||
| Canonical SMILES |
CC1=C(OC2=CC=CC=C12)CN(C)C(=O)C=CC3=CC4=C(NC(=O)CC4)N=C3
|
|||
| InChI |
1S/C22H21N3O3/c1-14-17-5-3-4-6-18(17)28-19(14)13-25(2)21(27)10-7-15-11-16-8-9-20(26)24-22(16)23-12-15/h3-7,10-12H,8-9,13H2,1-2H3,(H,23,24,26)/b10-7+
|
|||
| InChIKey |
QXTWSUQCXCWEHF-JXMROGBWSA-N
|
|||
| CAS Number |
CAS 620175-39-5
|
|||
| PubChem Compound ID | ||||
| Drug Resistance Mutation (DRM) | Top | |||
|---|---|---|---|---|
| DRM | DRM Info | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Staphylococcus Enoyl ACP reductase (Stap-coc fabI) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Fatty acid biosynthesis | |||
| Biotin metabolism | ||||
| Metabolic pathways | ||||
| Fatty acid metabolism | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Activity of AFN-1252, a novel FabI inhibitor, against Staphylococcus aureus in an in vitro pharmacodynamic model simulating human pharmacokinetics. J Chemother. 2013 Feb;25(1):32-5. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.